From Target to Translation: Revealing the Mechanism Behind HIF-2α Inhibition in Kidney Cancer

Behind the scenes of drug discovery, a fundamental question often remains unanswered: a treatment may show signs of working, but showing why it works and connecting that mechanism to patient outcomes is far harder.

A July 2026 Nature publication does exactly that for casdatifan, an investigational, small molecule HIF-2α inhibitor. The study is the first in this drug class to comprehensively connect the biology of kidney cancer tumors to a signal in the blood and, ultimately, to how patients have responded.

By combining tumor biology, blood-based biomarkers and clinical outcomes from the ARC-20 platform study, researchers showed that deeper suppression of the HIF-2α pathway with casdatifan correlated with stronger clinical activity across several measures, including longer progression-free survival and higher tumor response rates. The findings provide one of the clearest views yet into why targeting HIF-2α translates into improved patient outcomes.

The results do more than show that casdatifan is having an effect; they help explain how it’s working. By connecting pathway inhibition to patient outcomes, the study provides evidence that the clinical activity observed with casdatifan is linked to targeting a fundamental driver of kidney cancer rather than simply observing an unrelated treatment effect.

To understand more about these findings and what they could mean for people with kidney cancer, we spoke with Benjamin Weeder, Senior Bioinformatics Scientist and translational research lead on the paper; Richard Markus, MD, PhD, Chief Medical Officer; and Ken Lawson, Senior Director of Medicinal Chemistry at Arcus Biosciences.

What new evidence did the ARC-20 study add about targeting HIF-2α in kidney cancer?

Weeder: This study is the first to comprehensively connect tumor biology, a signal in the blood and clinical outcomes in patients receiving a HIF-2α inhibitor. In most kidney cancers, HIF-2α becomes chronically activated, switching on hundreds of genes, including those that help tumors survive and grow.^1,2

Erythropoietin (EPO) is a hormone whose production is regulated by HIF-2α but is not known to drive cancer growth itself.^3,4 When HIF-2α activity increases, EPO levels rise. Because EPO levels can easily be measured in the blood, it provides a direct readout of how well a therapy is blocking the HIF-2α pathway.

The study showed that casdatifan monotherapy reduced EPO levels, with consistent suppression that was maintained over time. Importantly, we found that deep and sustained reductions in EPO levels correlated with higher response rates and longer progression-free survival—the time people lived without their cancer worsening.

But the real breakthrough came when we connected these clinical trial results back to tumor biology. Using multiple independent metrics, including biomarkers in the blood and molecular analyses of the tumor tissue, we found the same pattern. People who had higher levels of HIF-2α activity in their tumor, and therefore more tumor EPO at baseline, experienced greater reductions in EPO levels in the blood and improved clinical outcomes with casdatifan. Together, these early findings connect tumor biology, HIF-2α pathway inhibition and clinical outcomes in patients receiving a HIF-2α inhibitor.

Why does connecting tumor biology to patient outcomes matter in kidney cancer?

Markus: In drug development, the challenge is often having a drug that is developed based on biological hypothesis and then showing that the intervention leads to clinically meaningful benefits to patients. In oncology, we generally use standard clinical endpoints such as progression-free survival and overall survival, but the data in ARC-20 go a step further and deeper by connecting the HIF-2α pathway inhibition to patient outcomes. In other words, the study doesn’t just show clinical activity—it helps explain the biological mechanism driving it.

That matters because people with metastatic kidney cancer still face significant challenges. Existing therapies can stop working over time, and many patients eventually experience disease recurrence and progression.⁵ The ARC-20 study specifically evaluated patients who had already been treated with other standard therapies, many of whom were treated with multiple options, and their cancers continued to grow. In the ARC-20 study, casdatifan monotherapy reduced tumor size in most patients, and patients lived two times longer without their cancer getting worse—12.2 months of progression-free survival—relative to published data from studies with the only marketed HIF-2α inhibitor in the same patient population.

The safety results from the trial were consistent with similar treatments like it and clinically manageable. Tolerability and safety are essential for any medicine, but especially for one that will be investigated in combination with other treatments. While these are early results, they strongly validate continued investigation of casdatifan for patients with advanced kidney cancer and beyond.

HIF-2α was once considered “undruggable.” What changed?

Lawson: HIF-2α is a tough target because it’s a large protein with a smooth surface that doesn’t offer many places for a medicine to bind.⁶

Eventually, researchers discovered a pocket where a small molecule could interact with HIF-2α and prevent it from functioning.⁷ That changed the field, but it didn’t make drug development easy. It was still a substantial design challenge to create a molecule that could fit precisely within this pocket while also meeting the requirements of a potential treatment.

That’s where medicinal chemistry becomes critical. The Arcus team spent years optimizing the design of casdatifan to specifically, strongly and stably bind to HIF-2α. These findings show that casdatifan is targeting HIF-2a as intended, translating into promising clinical outcomes.

What’s next for casdatifan in kidney cancer?

Article based on: Choueiri, Merchan, et al. “Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.” Nature, 2026

Casdatifan is an investigational molecule. Arcus has not received approval from any regulatory authority for any use globally, and its safety and efficacy for the treatment of renal cell carcinoma have not been established.